Navigation Links
Xenon to Collaborate with Genentech on Discovery of Novel Targeted Pain Therapeutics
Date:1/9/2012

VANCOUVER, British Columbia, Jan. 9, 2012 /PRNewswire/ -- Xenon today announced a strategic alliance with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), to discover and develop compounds and companion diagnostics for the potential treatment of pain.

"We are delighted to be collaborating with Genentech," said Simon Pimstone, President and CEO of Xenon. "Genentech is among the world's leading biotech companies and an ideal strategic partner for Xenon as we share a common emphasis on using human genetics for drug development.  Further, this collaboration allows Xenon to both deepen and broaden our pipeline of novel medicines in development."

Xenon and Genentech will collaborate on the discovery of new therapeutic approaches for treating pain. Under the terms of the agreement, Genentech has an exclusive license to compounds and a non-exclusive license to diagnostics from Xenon for development and commercialization of products. Xenon will receive an undisclosed upfront payment, research funding and is eligible to receive research, development and commercialization milestone payments, totaling up to $646 million for multiple products and indications.  In addition, Xenon will receive royalties on sales of products resulting from the collaboration. 

Michael Hayden, CSO of Xenon added: "This new alliance, which represents our sixth partnership with a major pharmaceutical company to date, once again highlights the keen interest in Xenon's unique genetics approach and in our translational R&D capabilities." 

About Xenon Pharmaceuticals Inc. (Xenon)

Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing small molecule therapies based on the genetic causes of select metabolic, neurological and cardiovascular diseases. For more information, visit the Company's website at http://www.xenon-
'/>"/>

SOURCE Xenon Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Xenon Chief Scientific Officer, Dr. Michael Hayden Receives Prestigious Award for Leadership in Medicine
2. Xenon Announces Appointment of EVP, Research & Development
3. DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs
4. FDA, Austen BioInnovation Institute to Collaborate on the Safety and Performance of Materials used in Medical Devices
5. Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis
6. Biospace Lab Collaborates With ImaBio Group to Develop a Unique X-Ray Tomographic Module for its Preclinical Imaging System
7. Roche, ChanTest Collaborate for Preclinical Cardiac Safety Testing of Drug Compounds Using iCell Cardiomyocytes and xCELLigence RTCA Cardio Instrument
8. OncoSec and Serametrix Collaborate to Identify Potential Biomarkers to Enhance Skin Cancer Immune Therapies
9. Medical Oncology Association of Southern California, Cardinal Health Specialty Solutions Collaborate With Payors to Improve Quality, Costs, Accessibility of Cancer Care
10. Awarepoint Corporation and MEDITECH Collaborate to Integrate Technology Platforms
11. World-Class Stem Cell Pioneers Collaborate & Educate at Texans for Stem Cell Research 2nd Annual Symposium In Austin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)...  Thoratec Corporation (NASDAQ: THOR ), a ... save, support and restore failing hearts, said today it ... On Tuesday, December 2, the company will participate ... Conference.  D. Keith Grossman , President and Chief ... beginning at 11:30 a.m., Eastern Standard Time (8:30 a.m., ...
(Date:11/26/2014)...  Cohen, Placitella & Roth, PC is investigating ... Nymox Pharmaceutical Corporation ("Nymox" or "Company") (NASDAQ: ... 31, 2011 through November 2, 2014 ("Class Period").  ... its officers and directors publically disseminated materially false ... and 20(a) of the Securities Exchange Act of ...
(Date:11/26/2014)... 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ... Drug Administration (FDA) has issued a Complete Response ... AVP-825. AVP-825 is an investigational drug-device combination product ... a novel Breath Powered delivery technology. ... with the preliminary feedback announced on November 7, ...
Breaking Medicine Technology:Thoratec Announces Presentations At Investor Conferences For December 2014 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4
... , NEW YORK, ... market research report is available in its catalogue. ... 2009 , http://www.reportlinker.com/p0164742/Global-Markets-for-Assisted-Reproductive-Devices-2009.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire ... U.S., 15 Countries in Europe and Japan. This ...
... Nov. 20 Cyberonics, Inc. (Nasdaq: CYBX ) today announced ... Chief Financial Officer, will present at the 21st Annual Piper Jaffray ... at 12:00 PM EST. The conference session and webcast will ... Piper Jaffray will host a webcast of the presentation live and ...
Cached Medicine Technology:Reportlinker Adds Global Markets for Assisted Reproductive Devices 2009 2Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 2
(Date:11/27/2014)... 2014 Blood-borne pathogens raise the risk ... and procedures in place to counter this. However, it ... things tainted with menstrual blood are taken as seriously. ... more sanitary way to handle tampons and menstrual pads ... Sonora, Calif. , He then created a prototype of ...
(Date:11/27/2014)... (HealthDay News) -- Most babies and young children don,t ... Food and Drug Administration says. Over-the-counter (OTC) cold ... younger than 2 because they could cause serious and ... adults average about three colds a year, but children ... parents might want to give them pain relievers, decongestants ...
(Date:11/27/2014)... NC (PRWEB) November 27, 2014 ... 12 years in the Charlotte area providing audits, ... examination services to businesses of varying size across ... business owners to meet all of their accounting ... certification through the QuickBooks ProAdvisor Program. When asking ...
(Date:11/27/2014)... Washington, DC (PRWEB) November 27, 2014 “Wekho” ... which features the latest and coolest mobile applications on the ... expert and host of NewsWatch, conducted the app review ... follow locations instead of people. , An interesting new way ... for iOS and Android devices. It’s called Wekho and ...
(Date:11/27/2014)... HealthPostures, a leading national designer ... announced that it has entered into a new ... will put HealthPostures' products into central Indiana’s premiere ... to having its products sold through Commercial Office ... with the business decision makers in the Indianapolis ...
Breaking Medicine News(10 mins):Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Jeffrey Carlini becomes Intuit Proadvisor and receives QuickBooks certification 2Health News:A New Geolocation Mobile Application and was Featured on NewsWatch Television on October 30, 2014 2Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2
... May Murphy from Glasgow was confirmed to have committed suicide five ... 75 years old and was suffering from degenerative disease// which made ... ,Mrs. Murphy wanted to end her life to escape from her ... Murphy went to Zurich with Dr. Michael Irwin and Jessica Reid. ...
... planning to introduce a Pilot scheme called 'Primary Care ... waiting to avail health care facilities in big hospitals.// ... to see their physician in outpatient facility for general ... without waiting for their appointment in big hospitals which ...
... on a 81 years old Romanian woman admitted to Matei ... has proved negative for the bird flu virus. The woman ... respiratory tract problem.// ,The old woman belonged to ... birds were detected and the entire village was quarantined and ...
... In an article published in the British Medical Journal, Nadine ... say that the ventilation systems supposed to prevent tobacco smoke ... ineffective. // ,The report also says ... systems do not work, but still proceeded to install them ...
... chief Pennsylvania Lt. Gov. Catherine Baker Knoll as said that still ... HIV infection. She is not happy with the Bush administration dealing ... Bush is not helping to tackle HIV infection spread and is ... become a great obstacle for prevention of HIV/AIDS infection. Due to ...
... new study by researchers at the UCSF School of Dentistry ... childhood tooth decay. // The use of varnish along with ... incidence of tooth decay in childhood, the study says. ... Hispanic backgrounds and divided them randomly into three groups. One ...
Cached Medicine News:Health News:Fluoride Varnish prevents Tooth Decay In Milk Teeth 2
Femoral selective diagnostic catheter.The material used is polyurethane (DUCOR). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
... The INFINITI 4F, ... of diagnostic catheters is ... These products incorporate state-of-the-art ... nylon to deliver better ...
... offering of cardiology catheters. Available in both ... designed with excellent torque, new wire-braid technology ... and large inner lumens for excellent flow ... 7 French sizes with pressure ratings up ...
Medicine Products: